Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV – Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine – – Phase 1 trial supported by the Bill & Melinda Gates Foundation,...

Sexually Transmitted Disease Testing Market revenue to exceed USD 145 Billion by 2033, says Research Nester New York, July 31, 2023 (GLOBE NEWSWIRE) -- The global sexually transmitted disease testing market size is predicted to grow at a CAGR of over ~6% from 2023 to 2035. The market is projected to...

Global HIV Treatment Market Report 2023: Enhanced Diagnostic Capabilities Fuels Growth Dublin, May 31, 2023 (GLOBE NEWSWIRE) -- The "Global HIV Treatment Market: Analysis By Product, By Region Size and Trends with Impact of COVID-19 and Forecast up to 2030" report has been added to ...

Vir Biotechnology Announces Initiation of Phase 1 Clinical Trial to Evaluate a Novel Vaccine Platform SAN FRANCISCO, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, announced...